Dr. Reddy’s launches anti-depressant tablets in U.S.
The Hindu
Launched following USFDA approval, the product is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150mg and 225mg, of Osmotica Pharmaceutical U.S. LLC.
Pharma major Dr. Reddy’s Laboratories has launched Venlafaxine ER Tablets in the U.S. market.
Launched following U.S. Food and Drug Administration (USFDA) approval, the product is therapeutically equivalent to Venlafaxine Extended-Release Tablets, 150mg and 225mg, of Osmotica Pharmaceutical U.S. LLC. A selective serotonin and norepinephrine reuptake inhibitor (SNRI), Venlafaxine Extended Release tablets are indicated for major depressive disorder (MDD) and social anxiety disorder (SAD).
More Related News